- Immunic's Q2 report on August 11, 2026, showed a GAAP EPS of -$0.80, beating analyst estimates of -$1.16 by $0.36.
- The company reaffirmed that top-line data for its pivotal Phase 3 ENSURE trials in relapsing multiple sclerosis remain on track for year-end 2026.
- Cash and cash equivalents of $155.1 million are expected to fund operations into late 2027.